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Ninety percent of the world’s HIV-positive pregnant women live in 
22 countries. These countries, including South Africa (SA), have 
prioritised the elimination of mother-to-child transmission of HIV 
(EMTCT), measured using three coverage and two impact indicators 
(Fig. 1).[1] The two impact indicators are the percentage mother-
to-child HIV transmission (MTCT) among HIV-positive mothers 
(MTCT risk) and the number of new paediatric HIV infections 
per 100 000 live births (MTCT case rate). The global target is <5% 
final MTCT in breastfeeding countries and ≤50 new paediatric HIV 
infections per 100 000 live births. Consequently, to achieve EMTCT, 
all 22 countries currently recommend lifelong antiretroviral treatment 
for all HIV-positive pregnant and lactating women. This is known as 
PMTCT Option B+. Between the 1980s and 2015 the discovery of 
more effective biomedical interventions to prevent mother-to-child 
transmission of HIV (PMTCT) accelerated the improvement of 
global and national PMTCT policies; such rapid advancements in 
policy required flexible, responsive health systems, services and staff 
to assure implementation.[1-6] For example, in 2001 the SA national 
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Background. Ninety percent of the world’s HIV-positive pregnant women live in 22 countries. These 22 countries, including South Africa 
(SA) have prioritised the elimination of mother-to-child transmission of HIV (EMTCT). Since 2016 all 22 countries recommend lifelong 
antiretroviral treatment for all HIV-positive pregnant and lactating women. To measure South African national, provincial and district-level 
progress towards attaining EMTCT, we analysed the number of in utero (IU) paedatric HIV infections per 100 000 live births (IU case rate), 
and synthesised factors hindering the monitoring of EMTCT progress and attainment from the viewpoint of provincial and district-level 
healthcare managers and implementers. We highlight potential innovations to strengthen health systems and improve EMTCT programme 
delivery.
Methods. We reviewed national-, provincial- and district-level birth HIV testing data from routine National Health Laboratory Services 
(NHLS) records between April 2016 and March 2017. To obtain a qualitative perspective from healthcare managers and implementers, we 
synthesised information from the nine 2016 provincial-level EMTCT stock-taking workshops. These workshops involve key provincial and 
district-level staff, mentors and supporting partners. Lastly, we highlight potential innovations presented at these workshops to overcome 
operational challenges.
Results. The national IU mother-to-child transmission (MTCT) rate was 0.9%, which translated to an IU case rate of 245 HIV-positive 
neonates per 100 000 live births. Provincial IU percent MTCT risk ranged from 0.6% to 1.3%, with IU case rates ranging between 168 
and 325 cases per 100 000 live births. District-level IU percent MTCT risk  ranged from 0.4% to 1.9%. Potential game changers include: 
pre-conception counselling to optimise maternal-partner health, weekly dissemination of HIV polymerase chain reaction (PCR) and viral 
load reports from the NHLS to specific individuals who trace mothers and infants needing care, use of ward-based outreach teams and 
community caregivers to trace HIV-infected mothers and their infants to link them into care, inclusion of a unique identifier in patient-held 
infant Road to Health booklets to facilitate infant tracing and continuous quality improvement (CQI) processes within facilities and districts 
and implementation of an HIV-positive baby tool to understand the characteristics and risks of HIV-positive infants. On an ecological level, 
provinces and districts using community-based approaches and CQI methodology seemed to have lower MTCT and IU case rates.
Conclusions. More quantitative analyses are needed to understand what proportion of the success can be attributed to community-based 
and CQI approaches and the impact of the potential game changers on progress towards EMTCT.
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PMTCT programme recommended single 
dose nevirapine (NVP) for HIV-positive 
pregnant women at the onset of labour 
and for HIV-exposed infants within 72 
hours of delivery. These recommendations 
were made alongside modified obstetric 
practices and avoidance or reduced duration 
of breastfeeding.[7] Between 2008 to 2013, 
national PMTCT improved dramatically 
to include the initiation of maternal 
antiretroviral drugs (ARVs) earlier in 
gestation or at higher CD4 cell counts.[8-10] By 
January 2015, the national PMTCT policy 
recommended lifelong triple antiretroviral 
therapy (ART) for all pregnant and lactating 
HIV-positive women (PMTCT Option B+ 
policy), with infant HIV testing at birth to 
identify in utero infection early, expedite 
ART initiation and improve infant outcomes, 
which are poor if ART initiation is delayed.
[11-12] In 2016, SA also launched the Last Mile 
Plan for EMTCT. This multipronged plan 
acknowledges the importance of delivery 
systems for EMTCT and prioritises five 
pillars, namely: (i) leadership, governance 
and coordination; (ii) scaling up PMTCT 
coverage; (iii) integrating PMTCT 
interventions into routine maternal and child 
healthcare (MCH) and primary healthcare 
(PHC); (iv) monitoring and evaluation; and 
(v) increased community awareness and 
involvement.[13] The PMTCT policy and 
Last Mile Plan require implementation at all 
levels of the healthcare system, during the 
preconception, antenatal and postnatal care 
periods, and involve mother, father, baby 
and in some instances the extended family, 
illustrating the complexities of PMTCT 
programme delivery. 
In a national-level review published in 
2017, we demonstrate that these policy 
changes yielded a concomitant decrease 
in the national risk of early (6 weeks 
postpartum) MTCT, from 3.5% in 2010 to 
1.1% in 2015-16 (Fig. 2).[13-16] Additionally, 
cross-sectional surveillance data suggest 
that ART initiation prior to conception 
or during the first trimester of pregnancy 
could reduce early MTCT to <1.2%.[14] 
Despite these national-level successes, inter-
provincial and inter-district differences in 
MTCT and maternal ART uptake exist: 
the provincial in utero  percent MTCT 
risk ranged from 1.4% to 5.9% in 2010 and 
0.7 - 1.7% in 2015/16; maternal ART uptake 
ranged from 78% to 98% in 2015/16.[14,15] 
The district-level early MTCT rate ranged 
from 2.2% to 8.1% in 2010 and 0% to 3.4% 
in 2015/16 (Fig. 2),[15,17,18] while maternal 
ART uptake varied from 46% to 100% in 
2015/16.[15] 
We analysed the number of IU paedatric HIV 
infections per 100 000 live births (IU case 
rate) as an initial step to monitor district- 
and provincial-level progress with EMTCT. 
Table 1. Definitions applied to routine NHLS data
Definition Numerator Denominator
Birth testing coverage: Total number of HIV 
PCR tests performed in HIV-exposed infants 
within the first 7 days
Total number of HIV PCR tests performed in 
neonates aged <7 days old
This is an estimate calculated from the DHIS 
total live births multiplied by the antenatal 
HIV seroprevalence rates obtained from the 
2013 national antenatal HIV seroprevalence 
survey[30]
IU % MTCT risk: % MTCT within the first 7 
days of life 
Neonates within the first 7 days of life with a 
positive HIV PCR test 
Total number of neonates tested during the 
first 7 days of life
IU case rates: Number of new HIV infections 
among- infants <7 days old expressed as a 
standardised rate per 100 000 live births
Number of HIV PCR-positive neonates per 
100 000 live births
Total live births obtained from the DHIS 
PCR = polymerase chain reaction; DHIS = District Health Information System; IU = in utero; MTCT = mother-to-child-transmission.
MTCT rate, as dened by WHO: % HIV-exposed infants who 
acquire HIV infection from their mothers
Case rate: number of new HIV infections in children 
per 100 000 live births 
In utero case rate: number of new HIV infections in 
children measured at <7 days of age, per 100 000 live births
Fig. 1. Key concepts in the elimination of mother-to-child transmission of HIV (EMTCT). 
Fig. 2. Early mother-to-child transmission measured at national, provincial and district levels in South Africa.
S19       March 2018, Vol. 108, (3 Suppl 1)
RESEARCH
Additionally, we synthesised factors that hinder the monitoring of 
EMTCT progress and attainment, from the viewpoints of provincial- 
and district-level healthcare managers and implementers. We have 
highlighted potential innovations to strengthen healthcare systems 
and improve EMTCT programme delivery. We include a focus 
on district-level, as opposed to a sole focus on national level data; 
inclusion of district-level data increases the granularity of our 
analysis. 
Methods
We aimed to deepen our understanding of district- and provincial-
level progress with eliminating MTCT using mixed methods 
(quantitative and qualitative). Thus, we sought data that represent 
an entire district or province, rather than data from one single clinic 
or hospital. 
Quantitative data review
Only two district-level sources of data are available in SA, namely the 
District Health Information System (DHIS) and the National Health 
Laboratory System (NHLS).[19] Data from the DHIS were muddied 
by the fact that changes to guidelines were not accompanied by 
changes to DHIS indicators. There have also been concerns about the 
accuracy and completeness of routine DHIS data.[20] Consequently, we 
analysed birth HIV testing data from the routine NHLS Corporate 
Data Warehouse (CDW), between April 2016 and March 2017. We 
focussed on NHLS data because the NHLS has protocols in place to 
clean and monitor data quality. We focussed on MTCT at birth for 
four reasons. Firstly, the SA National Department of Health (NDoH) 
recommends HIV testing at birth for all HIV-exposed infants. 
Secondly, no other data are available to determine the precise number 
of HIV-infected neonates. Thirdly, birth polymerase chain reaction 
(PCR) results are a marker of preconception and antenatal care for 
women. Fourthly, birth PCR results serve as an early warning sign of 
gaps in early infant diagnosis and PMTCT.
HIV PCR test data for HIV-exposed neonates tested before 
7 days of age were extracted from the NHLS CDW. A patient-linking 
algorithm using deterministic matching of patient demographics 
(using name, surname and date of birth) and probabilistic matching 
was used to identify duplicates among birth HIV tests and to 
deal with minor mismatches created by spelling errors. Additional 
manual matching was performed to ensure that HIV PCR-positive 
neonates were not doubly counted. Programmatic outcomes namely, 
birth testing coverage, IU percent MTCT risk, and IU case rates 
were calculated at national, provincial and district level from the 
de-duplicated data (Table 1). 
As maternal antenatal HIV sero-prevalence and number of live 
births influence the absolute number of IU-infected neonates, and 
the case rate, we separated provinces and districts into three antenatal 
HIV sero-prevalence categories of <25%, 25 - 35% and ≥35%. Within 
these categories, provinces with ≥90% and districts with ≥85% birth 
testing coverage, were ranked by case rates. 
Qualitative synthesis 
There are sparse published qualitative national-, provincial- or 
district-level data on factors affecting the monitoring of EMTCT 
progress and attainment, and innovative solutions to accelerate 
progress towards EMTCT. Consequently, to understand district-level 
perspectives, we reviewed reports from the provincial-level EMTCT 
stock-taking workshops conducted between April 2016 and March 
2017. These workshops are conducted annually, are co-ordinated by 
the NDoH across all 52 districts, and are part of the institutionalised 
monitoring and evaluation activities outlined in the National Action 
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Framework, 2011 - 2015, as well as the Last Mile Plan, 2016 - 2021.[13] 
The workshops provide an opportunity for districts to review district 
implementation plans (DIPs) and to track the achievement towards 
current targets.[21] All workshop reports were systematically reviewed 
by one author (WC) using the following framework questions: (i) what 
challenges are reported at provincial and district levels?; (ii) what game 
changers, i.e. radical innovations that fundamentally change PMTCT 
implementation, have been identified?;[23] and (iii) have the effects of 
the game changers been measured? This approach was consistent with 
our aims of moving away from a ‘broad-brushed’ national approach to 
understanding EMTCT progress, as well as increasing the granularity 
of our understanding. 
Results
Quantitative data review
Birth testing coverage was 93.5% (range 85% - 111% at provincial 
level); some percentages are >100% as denominators are estimated, 
leading to smaller denominators than the actual. The national 
percentage IU percent MTCT risk was 0.9%, which translated to a 
national IU case rate of 245 HIV-positive neonates per 100 000 live 
births. Provincial IU percent MTCT risk ranged from 0.6% to 1.3%, 
with IU case rates ranging from 168 to 325 cases per 100 000 live 
births (Table 2). The Western Cape, Free State and KwaZulu-Natal 
had the lowest case rates within each HIV prevalence category (Table 
2). District-level IU percent MTCT risk and IU case rates range from 
0.4% to 1.9% and 72 to 360, respectively (Fig. 3 and Table 3). 
Qualitative synthesis
The 2016/17 EMTCT stock-taking workshops identified several 
factors that hinder EMTCT attainment, including poor internet 
connectivity, poor alignment between routine indicators and 
programmatic interventions, lack of longitudinal monitoring, poor 
maternal viral load monitoring and inconsistent feeding advice 
(Fig. 4). Despite these challenges, the workshops highlighted the 
following points: (i) an increasingly strong focus on strengthening 
pre-conception, antenatal and postnatal maternal and child health 
services; (ii) alignment between PMTCT interventions, the last mile 
EMTCT plan and DIPs, to improve programme outcomes; (iii) an 
increased level of accountability at district and facility levels; (iv) 
that discussions enabled prioritisation of high MTCT districts; 
and (v) the importance of involving different district management 
team members (District Clinical Specialist Teams (DCSTs), PHC- 
and programme managers) in ongoing monitoring visits to ensure 
PMTCT integration into routine services. Ten potential game 
changers that are currently implemented to achieve fundamental 
healthcare system strengthening and durable improvement in the 
programme came to the fore (Fig. 4). Despite the fact that KwaZulu-
Natal (KZN) was the province with the second highest number of live 
births and had the highest antenatal HIV prevalence, its IU MTCT 
risk was the lowest of all provinces (0.6%), while its IU case rate was 
the fifth highest (250 per 100 000 live births). Ecological observations 
could attribute a portion of this success to the continuous quality 
improvement undertaken by the province: monthly teleconferences 
are held with district co-ordinators to review key indicators; PCR, 
antenatal care and postnatal care linkage forms are used to link 
mothers and children into care; and weekly teleconferences are held 
with facilities and districts to facilitate PCR monitoring.[23] 
Discussion 
Our quantitative analysis of birth MTCT data demonstrates varying 
MTCT risk and case rates by province and district, with no specific 
relationship between antenatal HIV prevalence, IU percent MTCT 
risk and case rates. The IU percent MTCT risk at birth was much 
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Fig. 3. Spatial distribution of IU case rates, by provincial antenatal HIV 
prevalence category.
1.   Poor internet connectivity and access to the weekly emails containing 
     the NHLS Results for Action reports. 
2.   Poor alignment between routine indicators and PMTCT programmatic 
     interventions. Additionally, non-reporting and inconsistent reporting 
     yield poor quality data. 
3.   Lack of longitudinal cohort monitoring.
4.   Poor maternal viral load monitoring.
5.   Inconsistent infant feeding advice or practices.
Fig. 4. Challenges identified during the elimination of mother-to-child 
transmissionstock-taking workshops.
Pillar 1: Leadership, governance and co-ordination 
• The shift in priority to district, subdistrict and facility levels, with support 
 from DCSTs and other managers.
Pillar 2: Scaling up coverage of PMTCT interventions
• Quality improvement interventions linking mothers to community-based 
 healthcare personnel
• The Mothers2Mothers ‘Mother Mentor’ programme, which facilitates coverage 
 and retention in care.
Pillar 3: Integrating PMTCT into MCH 
• Providing safe pre-conception services to couples: Two Gauteng-based services 
 have supported >800 couples with preconception care. There have been no recorded 
 vertical or horizontal HIV transmissions and early antenatal care booking rates have 
 improved for women achieving pregnancy. Additionally, no HIV-negative women have 
 tested HIV- positive at the time of pregnancy conrmation.
• A pre-printed unique identier (ID) in each Road-to-Health Booklet (image) is 
 being tested in the Tshwane District. This number can be used as an additional identier 
 on the NHLS laboratory form to facilitate continuity of care. 
 • The Positive Baby Tool, which retrospectively assesses where breakdowns in the
  PMTCT cascade occurred, culminating in a vertical HIV transmission. This helps districts 
 obtain a better understanding of their risk proles. 
Pillar 4: Best practices relating to monitoring and evaluation 
• Dashboards and cascades at facility and district levels that examine numbers as 
 well as percentages facilitate understanding of progress and risk
• The NHLS HIV PCR and Viral Load Results for Action reports provide weekly reports 
 to health personnel within districts and identify children that require follow-up 
Pre-printed unique ID
Fig. 5. Potential game changers to strengthen health systems and programme 
delivery for the elimination of mother-to-child transmission of HIV. (DCSTs 
= district clinical specialist teams; PMTCT = prevention of mother-to-child 
transmission of HIV; MCH = maternal and child health; NHLS = National 
Health Laboratory Service; PCR = polymerase chain reaction.)
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lower than the 5% MTCT target, which demonstrates success 
(Fig. 1 and Tables 2 and 3), but IU case rates at the district level are 
up to seven-fold higher than the global target. IU case rates depend 
on the number of HIV-exposed infants, and thus maternal HIV 
prevalence. From the synthesis of district-level discussions, several 
game changers are currently being implemented in a non-systematic 
way to strengthen healthcare systems and close the gaps in EMTCT 
programme delivery in SA. The implementation of any game changer 
requires close collaboration between health facilities, laboratories, 
communities, healthcare staff and supporting partners as data from 
Uganda demonstrate that the failure to strengthen healthcare systems 
could be a rate-limiting step to sustainable PMTCT success.[24] 
Evidence demonstrates that PMTCT programme outcomes improve 
after integration into the mainstream routine healthcare system 
for maternal and child health.[25] Game changers should not add to 
the complexity of PMTCT implementation, but should strengthen 
routine systems to improve service delivery. 
One key stumbling block to the attainment of EMTCT is 
poor monitoring of maternal viral suppression. Data from 
more experienced Option B+ countries corroborate this key 
challenge.[26,27] In fact, a systematic review and meta-analysis in 
51 countries demonstrated 73.5% overall ART adherence (defined as 
>80% intake of recommended pill doses), which disaggregates into 
75.7% during pregnancy and 53.3% postnatally.[26] Being on triple 
antiretroviral therapy rather than prophylaxis reduced the odds 
of adherence.[26] Individual-level data from 19 facilities in Malawi 
demonstrated that ART initiation among pregnant women with 
high CD4 cell counts were five times more likely to miss follow-
up visits and women who started ART while breastfeeding were 
twice as likely to miss follow-up visits, compared with pregnant 
women needing ART for their own health.[27] This begs the question: 
Why do women not adhere to their ART and follow-up visits? SA 
data demonstrate that conflict with work commitments, negative 
treatment from healthcare workers and the lack of disclosure reduce 
retention in care, and by deduction, adherence.[28] HIV viral load 
monitoring is now even more critical following the 2016 WHO 
infant feeding update, which recommends exclusive breastfeeding 
for 6 months and continued breastfeeding  for 24 months or longer 
for HIV-negative and HIV-positive women.[29] Thus, strengthening 
healthcare systems and implementing game changers that promote 
retention in care and infant follow-up are urgently needed. 
Ongoing monitoring and in-depth qualitative and quantitative 
studies are needed to identify high-burden districts and to test the 
impact of potential game changers on maternal and child health 
outcomes. 
Conclusion
IU percent MTCT risk is significantly less than the 5% final MTCT 
global target however, final MTCT rates at the district, provincial 
and national levels need to be closely monitored, as we anticipate a 
national increase in breastfeeding prevalence after the 2016 infant 
feeding update. IU case rates are considerably higher than the global 
target, because of high maternal HIV prevalence. We hypothesise a 
possible link between using community-based approaches and CQI 
and lower IU percent MTCT risk/IU case rates in one province 
(KZN) with the highest antenatal HIV prevalence. However, 
more in-depth studies and data are needed to understand what 
quality improvement methods have the greatest impact and what 
proportion of the success can be attributed to community-based 
approaches. More district-level systematic studies are needed, to 
quantify bottlenecks to EMTCT and to test the impact of potential 
game changers on the health, development, growth, and HIV-free 
survival of HIV-exposed infants until breastfeeding cessation, and 
the health of their mothers. 
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